aaiPharma Inc. is a science-based, specialty pharmaceutical company with more than 22 years of drug development experience. Focusing on targeted therapeutic areas, the Company markets a growing portfolio of established branded products and applies innovative technologies to increase the commercial potential of these products. At the same time, aaiPharma's research and development organization is developing an impressive pipeline of products to position the Company for near-term and long-term growth in its targeted therapeutic areas. In addition to developing and marketing its own line of proprietary pharmaceutical products, aaiPharma continues to be a world leader in providing contract pharmaceutical development services through its AAI International division. NOTE: Merger with CIMA Labs announced 8/05/2003, terminated 11/03/2003.

Wilmington, North Carolina

Abbott Laboratories, Inc. For more than a century, Abbott Laboratories has been working to advance health care for people around the world. Founded by a young Chicago physician, Dr. Wallace Calvin Abbott, in 1888, Abbott Laboratories has evolved into a diversified health care company that discovers, develops, manufactures and markets innovative products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. Headquartered in north suburban Chicago, Abbott helps people around the world in the more than 130 countries. Building leadership and combining strengths in the areas of pharmaceuticals, nutritionals, hospital products and diagnostics has enabled Abbott to provide total, integrated solutions across the health care spectrum for some of the world’s most prevalent medical conditions, including AIDS, cancer and diabetes. We focus on advancing medical science and the practice of health care with expertise in the therapeutic areas of diabetes, pain management, respiratory infections, HIV/AIDS, men and women’s health, pediatrics and animal health.

Abbott Park, IL

We are a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including cancer, inflammatory and autoimmune disorders, transplant-related diseases, cardiovascular disease and infectious diseases. We have proprietary technologies that facilitate rapid generation of highly specific, antibody therapeutic product candidates that contain fully human protein sequences and that bind to disease targets appropriate for antibody therapy. We refer to these candidates as fully human antibody therapeutic candidates. We developed our XenoMouse® technology, a technology using genetically modified mice to generate fully human antibodies. We also own a technology that enables the rapid identification of antibodies with desired function and characteristics, referred to as SLAM™ technology. In our XenoMax™ technology, we use SLAM technology to select and isolate antibodies with particular function and characteristics from antibody-producing cells generated by XenoMouse animals. We believe XenoMax technology enhances our capabilities in product development and flexibility in manufacturing. We intend to use our technologies to build a large and diversified product portfolio that we expect to develop and commercialize through licensing arrangements with pharmaceutical companies and others, through joint development and through internal product development programs. We have entered into a variety of contractual arrangements with multiple pharmaceutical, biotechnology and genomics companies involving our XenoMouse technology. Two of our customers, Pfizer and Amgen, have initiated clinical trials with fully human antibodies generated from XenoMouse animals. In addition, as of March 31, 2002, we had four proprietary antibody product candidates in clinical trials, one of which we had agreed to co-develop and commercialize with Immunex Corporation and one of which we had agreed to co-develop and commercialize with SangStat Medical Corporation.

Fremont, California

ActivBiotics is a clinical stage company committed to significantly improving the treatment of acute infections and chronic diseases caused or exacerbated by microbial pathogens. The Company's lead compound, rifalazil, is being investigated in a Phase II trial for sexually transmitted diseases and is preparing to enter Phase II trials in other indications. In addition, the Company has a highly productive program to develop proprietary new chemical entities. The program is producing both narrow and broad spectrum compounds with unprecedented potency and concomitantly improved resistance profile.

128 Spring Street
Lexington, Massachusetts 02421

Adolor Corporation is a late-stage biopharmaceutical company committed to the development and commercialization of novel products to relieve pain and reduce the side effects of currently marketed narcotics. Adolor’s lead product candidate, alvimopan™, is a first-in-class compound that is in Phase 3 clinical trials for two indications: post-operative ileus and opioid bowel dysfunction, both of which represent large unmet medical needs. The company is also developing a series of next-generation peripherally acting kappa opioid compounds for the treatment of pain associated with acute and chronic inflammatory diseases. These compounds have the potential to revolutionize existing pain management markets because of their ability to relieve pain as effectively as morphine and other opioid narcotics, without the severe adverse side effects and addiction potential associated with opioid narcotics. Adolor’s strategy is to combine near-term commercialization opportunities with a longer-term approach to develop novel opioid analgesics based upon a new molecular understanding of the function of opioid receptors. Adolor combines the expertise of world leaders in molecular biology, pharmacology and chemistry with experienced pharmaceutical and biotechnology management. As Adolor moves towards commercialization, the company continues to add key personnel with clinical development, regulatory and commercialization expertise. The Company’s strategic goal is to establish a pharmaceutical franchise in pain management.

Exton, Pennsylvania

Aerogen, an emerging specialty pharmaceutical company, is developing inhaler and nebulizer products, based on its proprietary aerosol generator technology, for the treatment of respiratory disorders in the home and hospital markets. Aerogen is also applying its technology to develop products in collaboration with pharmaceutical and biotechnology companies for the treatment of respiratory and other disorders. Aerogen now markets two Aeroneb nebulizer systems, one optimized for professional use in the hospital and the other for home use.

Mountain View, California

AEterna Laboratories has an extensive portfolio of marketed and development-stage biopharmaceutical products focused in oncology and endocrinology. Its lead oncology compound is Neovastat®, a proprietary angiogenesis inhibitor with multiple mechanisms of action in a Phase III clinical trial for renal cell carcinoma (data available by year-end 2003) and in a Phase III trial for non-small cell lung cancer. Cetrotide®, its lead compound in endocrinology is sold in the U.S. and Europe to the "in vitro" fertilization market, and is in clinical testing for endometriosis, uterus myoma and enlarged prostate (BPH). A further seven clinical programs are underway with various compounds.

1405 Parc-Technologique Blvd.
Quebec City, Quebec, CANADA G1P 4P5

From its inception more than 50 years ago, Alcon has committed itself to the discovery and development of specialty pharmaceuticals that address both chronic and acute diseases of the eye. We are committed not just to the treatment of a single eye disease or disorder, such as gluacoma, but to all of the major diseases of the eye including infection, inflammation, allergy, dry eye and macular degeneration. Over the years, Alcon has become the global leader in specialty ophthalmic pharmaceuticals, with the broadest array of products of any company in the industry around the world. With a large sales force covering ophthalmologists, optometrists, pediatricians, allergists and primary care physicians, we are uniquely positioned in the industry to market effectively to all physicians and eye care professionals who might prescribe our eye medications.

Fort Worth, Texas

Alexion's strategy is to build on its strong scientific and product development base to develop novel antibody therapeutics targeting the treatment of patients with a wide array of severe disease states, including cardiovascular and autoimmune disorders, inflammation and cancer. Alexion is dedicated to developing effective and safe treatments for human diseases for which treatment options are either non-existent or inadequate.

Cheshire, Connecticut

Alfacell is a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonucleases (RNases). Our mission is to develop new therapeutics from our novel ribonuclease technology platform for the treatment of cancer, infectious diseases and other life threatening conditions, thus offering new horizons of hope for patients and physicians.

225 Belleville Avenue
Bloomfield, New Jersey 07003

Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people's lives.

Irvine, California

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin's lymphoma.

11080 CirclePoint Road Suite 200
Westminster, Colorado 80020

Alnylam is the leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health(TM). Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Ribopharma of Kulmbach, Germany. Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders

790 Memorial Drive, Suite 202
Cambridge, Massachusetts 02139

Headquartered in Southern California, Alpha Therapeutic has offices and facilities throughout the United States. A subsidiary, Alpha Therapeutic Services, is a nationwide provider of home infusion products and services. In addition, the company has international affiliates in the United Kingdom, Germany, Spain, Italy, Thailand and Singapore.

Los Angeles, California

Marketing the broadest portfolio of specialty pharmaceuticals in the industry with over 150 products in both prescription and over-the-counter categories, Alpharma USPD is a major generic drug company with a substantial presence in consumer pharmaceuticals. Items are available in a wide range of product categories from respiratory and cough/cold to first aid and women's health. We are dedicated to providing our customers with the highest quality generic pharmaceuticals.

Baltimore, Maryland

ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with leading drug delivery technologies. ALZA applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical companies as well as for its own portfolio. ALZA's strategy for building its commercial presence is to target specialty market opportunities, with a focus on urology, oncology and central nervous system (CNS) products. By developing, acquiring and marketing products in these areas, ALZA is establishing strong relationships with key physicians while providing a range of therapies to treat the individual needs of patients.

Mountain View, California

Amgen, Inc. Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). At the time, Amgen's corporate mission was to be the world leader in discovering, developing and manufacturing cost-effective human therapeutics based on advances in cellular and molecular biology. Currently, Amgen's Aspiration statement is to be the best human therapeutics company. We will live the Amgen values and use science and innovation to dramatically improve people's lives. In-depth knowledge developed through the utilization of state-of-the-art cellular and molecular biology enables Amgen scientists to discover and develop both naturally occurring proteins and small molecules as potential human therapeutics.

Thousand Oaks, California

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. The Company’s two late-stage, first-in-class diabetes product candidates – SYMLIN® (pramlintide acetate) and exenatide (synthetic exendin-4) – are being developed to address the global epidemic of diabetes. Amylin has a strategic alliance with Eli Lilly and Company for the co-development and global commercialization of exenatide, and an extended release formulation, exenatide LAR. Building on its experience in the diabetes field, the Company is developing candidates for cardiovascular disease and obesity by utilizing its research experience with the metabolic properties common to all three conditions.

9373 Towne Centre Drive
San Diego, California 92121
  (858) 552-2200

Andrx Corporation is a specialty pharmaceutical company that applies its ten proprietary and patented oral controlled-release drug delivery technologies and formulation skills to the research and develoment of bioequivalent/generic (ANDA) and brand/proprietary (NDA) products. In its generic program, Andrx primarily develops bioequivalent versions of controlled-release brand products as well as difficult to replicate specialty, niche or immediate release brand name pharmaceuticals. In its brand program, Andrx applies its oral controlled-release technologies and formulation skills to develop improved versions of existing brand drugs, which will be marketed as new brand pharmaceuticals. Andrx also markets and distributes, primarily to independent pharmacies, pharmaceutical products manufactured by third parties.

Weston, Florida

Angiogene is a drug discovery company targeting diseases involving active angiogenesis. The company was originally formed in 1993 to exploit the expertise and intellectual property of the founding scientist, Dr. Graeme J. Dougherty, in the areas of gene therapy and vascular biology. Angiogene established its U.K. Office in 1996 and was registered in Scotland in 1997 as Angiogene Pharmaceuticals Ltd. The company's research is presently carried out at laboratories in the U.K. and in North America. In 1998 Angiogene secured its first major partnership with a large pharmaceutical company, licensing ANG453 to AstraZeneca. Renamed ZD6126, this compound is now in Phase I.

Oxfordshire, United Kingdom

Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of products for pediatricians. Founded in 2006, Arbor actively seeks out unique, patent-protected therapies proven to effectively treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US.

4505 Falls of the Neuse Road, Suite 420
Raleigh, North Carolina 27609

Manufacturing, marketing and import/export of pharmaceuticals, quasi-drugs, foods and medical supplies and systems, and home care business, etc.

Astellas Pharma was formed from the merger of Fujisawa Pharmaceuticals and Yamanouchi Pharmaceuticals in April 2005.

3-11, Nihonbashi-Honcho 2-Chome, Chuo-Ku
Tokyo, Japan
AstraZeneca Corporation AstraZeneca is one of the world's leading pharmaceutical companies. Backed by a strong research base and extensive manufacturing and commercial skills, we provide innovative, effective medicines that make a real difference for patients in important areas of healthcare. We aim to be the first with new ideas and innovative in all areas of our activity to create value for our customers, shareholders, employees and the communities in which we work. AstraZeneca provides innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control and respiratory.

London, United Kingdom

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clinical testing arena to ultimately establish the safety and efficacy of novel compounds that address serious unmet medical needs AtheroGenics has assembled two synergistic technology platforms. Our proprietary v-protectantTM technology platform has been the foundation of our discovery research efforts, and is the basis of our first three compounds, currently in clinical development.

8995 Westside Parkway
Alpharetta, Georgia 30004
  (678) 336-2500

AVANIR Pharmaceuticals is a drug discovery and development company that has a commercialized FDA-approved product and a product in Phase III clinical trials. AVANIR is engaged in small molecule research to develop treatments for central nervous system disorders and inflammatory diseases. Through its subsidiary, Xenerex Biosciences, AVANIR also develops human monoclonal antibodies for therapeutic applications.

San Diego, California

Aventis US Aventis is now part of the sanofi-aventis Group. The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines. .

Bridgewater, New Jersey

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer.

One SW Columbia Suite 1105
Portland, Oregon 97258

Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and Europe. Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of gastrointestinal diseases and disorders. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on distribution of products and offers potential licensors the prospect of rapidly expanding the potential market for their products.

Mont-Saint-Hilaire, Québec, Canada

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease, human memory disorders and prion-based illnesses such as Mad Cow Disease.

New York, New York

Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in developing, manufacturing and marketing generic and proprietary pharmaceuticals.

2 Quaker Road, PO Box 2900
Pomona, New York 10970

Barrier Therapeutics, Inc. is a specialty pharmaceutical company focused on the development of novel dermatological therapeutics. The privately held company was formed to develop and market dermatological products based on intellectual property initially in-licensed from affiliates of Johnson & Johnson.

100 Overlook Center 2nd Floor
Princeton, New Jersey 08540
  (609) 375-2200

Bausch & Lomb is a global eye care company dedicated to helping consumers see, look, and feel better through innovative technology and design. Founded in 1853, the company has annual revenues of approximately $2 billion and employs approximately 12,000 people in 35 countries. Bausch & Lomb products are available in more than 100 countries around the world. Bausch & Lomb has three product lines: Vision Care, Surgical, and Pharmaceuticals.

Rochester, New York

Bayer Pharmaceuticals North America conducts business in three major areas of health care: prescription medications, biological products, and biotechnology. Bayer is also one of the world's largest producers of allergenic extracts, which are used by allergy professionals to desensitize patients suffering from various forms of allergy.

Pittsburgh, Pennsylvania

Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company has established a therapeutic platform of autoimmune modulators, in-licensed from Stanford University, that address the broad market of Th1 mediated autoimmune diseases. The Company's initial disease focus is multiple sclerosis, with its first product (BHT- 3009) entering Phase I/II studies in the first quarter of 2004. In addition, the Company has a strong portfolio of product programs focused around individual agents with demonstrated proof of concept as autoimmune modulators (AIM(TM)), as well as in the combination of these modulators in a proprietary manner, AIMTx(TM).

3430 W. Bayshore Road Suite 201
Palo Alto, California 94303
  (650) 846 7800

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of branded and generic pharmaceuticals in Spain for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar.

Bentley Park
Exeter, New Hampshire 03833

Berlex Laboratories, Inc., located in Wayne and Montville, NJ and Richmond, CA, is committed to bringing to the market beneficial preventive, diagnostic and therapeutic medicines in the strategic fields of Dermatology, Diagnostic Imaging, Female Healthcare, Therapeutics and Oncology. Driving our activities is a three-pronged emphasis on recognizing and addressing marketplace needs, improving the quality of life for patients and building strong relationships with the healthcare professionals who select and administer our pharmaceutical products.

Montville, New Jersey

In November 2003, Biogen Idec Inc.(NASDAQ: BIIB) was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure, and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing. Biogen Idec is dedicated to pursuing the creativity of science. The company’s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology. nbsp; Merger of Biogen with IDEC Pharmaceuticals finalized 11/12/2003.

Cambridge, Massachusetts

Biovail Pharmaceuticals Inc. markets Biovail and in-licensed products to physicians, pharmacists and hospitals across the United States. It was created in 2000, through the acquisition of DJ Pharma Inc., providing Biovail with an established network of U.S. sales professionals. Since its inception, Biovail Pharmaceuticals Inc. has enhanced Biovail's presence in the U.S. marketplace through aggressive sales force expansion and the launch of new pharmaceutical brands. Current products in its portfolio include Cedax®, Rondec®, Teveten®, Zovirax®, Cardizem®, Vasotec® and the Vaseretic® product line. This portfolio will be expanded through product licensing and acquisitions, as well as the addition of branded products developed by Biovail. Biovail Corporation (headquartered in Mississauga, Ontario, CANADA) is a full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacturing, sale and promotion of pharmaceutical products by utilizing advanced oral controlled-release and FlashDose® technologies.

Morrisville, North Carolina

Boehringer Ingelheim Corporation Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Boehringer Ingelheim corporation is a family-owned company. It is owned by a committee of private shareholders dedicated to the long term interests of the corporation´s stakeholders, including its customers, employees and the communities within which it operates. This distinctively independent structure makes it more possible to operate according to long term strategies rather than short term priorities. Best selling Prescription Medicines products: Combivent®, Flomax®, Atrovent®, Catapres®, Mobic®

Ridgefield, Connecticut

Boston Life Sciences, Inc. (BLSI) is a development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic solutions for central nervous system diseases (CNS) and cancer. BLSI's products in development include: ALTROPANE® and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Boston, Massachusetts

Bristol-Myers Squibb Company Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. At Bristol-Myers Squibb, our mission is to extend and enhance human life by providing the highest-quality health care products and services. Our medicines are making a difference in the lives of millions of customers across the globe. And by living our mission and growing our company for well over a century, we are making a difference in the lives of our shareholders, employees and neighbors as well.

New York, New York

Cambridge Antibody Technology (CAT) is a world leading company in the discovery and development of human monoclonal antibody therapeutics. Using its pioneering technologies, CAT has developed an impressive pipeline of novel human monoclonal antibody drugs. Six of these are currently at various stages of clinical trials, with a seventh (D2E7) having been submitted for regulatory review, following the completion of Phase III trials for the treatment of rheumatoid arthritis. The Company's business is driven from a proprietary platform of phage display technologies. To maximise commercial opportunities, CAT has built an array of strategic collaborations with leading pharmaceutical and biotechnology companies worldwide.

Cambridge, United Kingdom

CBD Health Collection is a woman owned, small business based in the USA. Our mission is quite simple: To deliver the highest quality CBD products for health and wellness; with a commitment to full transparency. We focus on a medical/scientific approach to the CBD market. We are currently looking for 1099 partners to market our products to pain centers, family physicians, physical therapy and rehabilitation centers, osteopaths, chiropractors, essential oil practitioners, holistic health practitioners, acupuncturists, massage therapists, sports gyms and sports teams. We also have a pet product line for Veterinarians.

5195 Hampsted Village Center Way, Unit 96
New Albany, OH 43054
  1 614 907-3392
Celgene Corporation is a specialty pharmaceutical Company engaged in the development and commercialization of human pharmaceuticals and agrochemicals. It employs two broad technology platforms: (i) small molecule immunotherapeutic compound development and (ii) biocatalytic chiral chemistry. The focus of the immunology program is the development of small molecule pharmaceuticals that selectively regulate Tumor Necrosis Factor alpha (TNF-alpha), a protein whose overproduction has been linked to many chronic inflammatory and immunological diseases. The company's lead compound is THALOMID® which was approved in 1998. THALOMID (thalidomide) which is currently indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID (thalidomide) is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID (thalidomide) is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Celgene has further applied its expertise in small molecule chemistry to develop novel and proprietary thalidomide analogues, called IMiDs™(Immunomodulatory Drugs) as well as a class of proprietary immunotherapeutic compounds called SelCIDs™ (Selective Cytokine Inhibitory Drugs) both of which are highly specific modulators of TNF-alpha.

Warren, New Jersey

Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged in the development and commercialization of prescription drugs with primary focus in the areas of gastroenterology, sexual dysfunction and women's health care. Cellegy has developed expertise in the use of nitroglycerin ointment and nitric oxide donors to address a number of serious conditions. Cellegesic(TM) ointment for the treatment of anal fissures and hemorrhoids is currently awaiting FDA protocol approval of a confirmatory Phase III clinical trial to treat the severe pain associated with chronic anal fissures. The Company is also conducting clinical trials using Cellegesic to treat hemorrhoids. Other nitroglycerin based product candidates, in earlier clinical development, are targeting conditions including female sexual dysfunction, Raynaud's disease and prostate cancer. Cellegy is also developing a second testosterone product, Tostrelle(TM) Gel for the treatment of female sexual dysfunction. Tostrelle is undergoing a phase II / III clinical trial in the United States and has generated significant interest from potential partners and the medical community.

South San Francisco, California

CeMines(TM) is a new-generation biotechnology company that applies the principles of gene regulation in development of early-stage diagnostics and targeted therapeutics for cancers and other diseases, based on the Company's patent-pending, proprietary biomarker technology known as CeMines Molecular FingerPrinting(TM). CeMines™ has developed its breakthrough Molecular FingerPrinting™ blood test for the early-detection and optimized treatment of a variety of cancers and other immune diseases. Based on monitoring disease-specific molecular changes in gene regulatory machinery, CeMines™ believes that its minimally invasive diagnostic tests will provide accurate, early detection of most widespread cancers --including lung, breast, prostate and gastrointestinal - and can provide critical information in optimal treatment modalities.

La Jolla, California
  303 679-3150

Building on our leadership position in monoclonal antibody technology, Centocor creates, acquires and markets unique biopharmaceutical therapies. Our innovative products focus on the management of three major disease areas; cardiovascular, immunologic disorders and cancer. Centocor is proud to be part of the Johnson & Johnson family of companies.

Malvern, Pennsylvania

Cephalon seeks to discover, develop and market innovative products to treat neurological and sleep disorders, cancer, and pain. The company is committed to providing patients and the medical community with novel therapies to treat unmet medical conditions through its proprietary research programs and by acquiring promising products for clinical development and commercial sale. Our success is supported by a proven strategy of marketing high-growth, innovative products, building our worldwide marketing and distribution channels, and investing in research and development of unique compounds that may change the course of a disease. An international biopharmaceutical company headquartered in West Chester, Pennsylvania, with offices and manufacturing facilities in Salt Lake City, Utah. Cephalon's major European offices are located in Guildford, England, and at Laboratoire L. Lafon, in Maisons-Alfort, France. Founded in 1987 by Frank Baldino, Jr., Ph.D. Co-founders: James Kauer, Ph.D. and Michael Lewis, Ph.D. Three growth products marketed in the United States and more than twenty products marketed globally. Revenue from product sales in 2001 was $226.1 million vs $91.6 million in 2000. Approximately 1,200 employees in the U.S. and Europe. Merger with CIMA LABS announced 11/03/03.

West Chester, Pennsylvania

Chiron Corporation is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. The company has a strategic focus on cancer and infectious disease. Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. The company commercializes its products through three business units: vaccines, blood testing, and biopharmaceuticals.

Emeryville, California

Chugai Pharma USA, LLC discovers and develops therapeutic products that treat cardiovascular diseases, cancer, plus gastrointestinal and joint diseases. Our 72,000-sq. ft. facility in San Diego, California houses molecular biology, biochemistry, as well as high throughput screening, medicinal chemistry laboratories, and a large clinical development team. In line with our overall mission, Chugai Pharma USA is developing the infrastructure required to commercialize therapeutic drug products in the US. At CPUSA we strive to maintain a working environment that offers our employees ample opportunities and resources to realize their full potential and to advance within the organization.

San Diego, California

CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies, OraSolv® and DuraSolv®. Based on these technologies, an active drug ingredient, which the company frequently taste-masks, is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. CIMA's business involves a dual operating strategy. The company develops and manufactures orally disintegrating versions of drugs for pharmaceutical company partners for whom CIMA currently produces three branded prescription pharmaceuticals and three over-the-counter brands. CIMA is also developing proprietary products utilizing its orally disintegrating technologies, as well as its new OraVescent® enhanced absorption, transmucosal drug delivery technology. NOTE: Merger with aaiPharma originally announced 8/05/2003, was terminated 11/03/2003.Merger with Cephalon, Inc. announced 11/03/03.

10000 Valley View Road
Eden Prairie, Minnesota 55344

Medicare Advantage Health Plan

Wil Yu
Confluent is a private medical device company founded in August 1998, that is pioneering the development of In-situ-polymerized Biomaterials. These materials have almost universal applications across minimally invasive surgery, because they allow the safe, simple, and rapid, formation of customized implants at the site of disease. This process can take place rapidly when two aqueous solutions of molecularly designed synthetic polymers mix together. Confluent's vision is to address unmet needs in surgery and interventional procedures using its technology platform of in situ polymerization.

Waltham, Massachusetts

Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05% and Luxiq(R) (betamethasone valerate) Foam, 0.12%. The Company also is developing Extina(TM), a foam formulation of the antifungal drug ketoconazole, and Actiza(TM), a foam formulation of clindamycin for treating acne. Connetics also recently in-licensed Velac(R) gel, a combination acne therapy. These formulations aim to improve the management of dermatological diseases, provide significant product differentiation, and extend product life cycles.

Palo Alto, California

Cook Surgical markets medical biomaterials from acellular natural tissues through its tissue engineered products group. In addition, the company's growing team of medical device engineering and development specialists works with leading researchers at hospitals and university medical centers around the world to develop, test and perfect important new diagnostic and interventional medical products.

Bloomington, Indiana

Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development of innovative gene therapy products for the treatment of cardiovascular disease. Corautus Genetics was formed by the merger of Vascular Genetics Inc. with GenStar Therapeutics Corporation to capitalize on the complementary strengths of these companies to accelerate the development of a later stage product for cardiovascular disease. Corautus Genetics' core technology is based upon gene therapy for "therapeutic angiogenesis." In this approach, the injection of genes for vascular growth factors stimulate the formation of new blood vessels to help compensate for reduced blood flow due to advanced cardiovascular disease. The focus of the company's efforts will be the clinical development of gene therapy products using a vascular growth factor gene (Vascular Endothelial Growth Factor 2 or "VEGF-2") for the treatment of severe cardiovascular disease.

6555 Nancy Ridge Drive
San Diego, California 92121

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, BEXXAR®, a monoclonal antibody conjugated to a radioisotope.

Seattle, Washington

Corus Pharma seeks to develop drugs to treat unmet needs in the infectious diseases and respiratory areas. The company's core competencies reside in the identification of drug candidates, rapid clinical development and FDA approval of its products. Target development candidates will be identified through a combination of internal ideas, academic research and a search of projects in other organizations.

2025 1st Avenue Ste 800
Seattle, Washington 98121
  206 728-5090

Corvas International, Inc. is a biopharmaceutical company focused on the development of new biotherapeutics that address large medical markets, including cancer and cardiovascular disease. rNAPc2, Corvas' cardiovascular drug candidate currently in Phase II clinical trials, is a novel anticoagulant intended for the treatment of people affected by acute coronary syndromes, which include unstable angina and non-ST-segment elevation myocardial infarction. Corvas' cancer research programs are focused on the development of new biotherapies, including monoclonal antibodies and synthetic prodrugs, that target serine proteases associated with the growth and spread of cancerous tumors. Note: Merger with Dendreon Corporation approved by Corvas shareholders on 7/28/2003.

San Diego, California

Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel pharmaceuticals to combat serious and life-threatening infections. Cubist is evaluating the safety and efficacy of Cidecin(R) (daptomycin for injection) in the EDGE(TM) (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre-clinical drug candidates, including an oral version of ceftriaxone (OCTX), a broad-spectrum cephalosporin antibiotic, and CAB-175, a next generation cephalosporin antibiotic with demonstrated in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). The company is engaged in a strategic partnership with Novartis Pharma AG for the discovery and development of novel antiinfectives.

Lexington, Massachusetts

CV Therapeutics, Inc. CV Therapeutics is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has four compounds in clinical trials. If approved by the FDA, Ranexa would represent the first new class of anti-anginal therapy in more than 20 years. Tecadenoson, an A1-adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146, a selective A2A-adenosine receptor agonist, is being developed for potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment of acute and chronic congestive heart failure, is licensed to Biogen, Inc.

3172 Porter Drive
Palo Alto, California 94304

Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, state-of-the-art RNAi functional genomics, chemogenomics and clinical biomarker technologies to rapidly deliver new drugs.

Dundee Technopole
Dundee, United Kingdom DD1 5JJ
  +44 1382 206 062

Cytogen Corporation is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and BrachySeed(TM) Pd-103 (two uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and NMP22(R) BladderChek(TM) (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet(R), a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company receives royalties on product sales through Berlex Laboratories, the U.S. affiliate of Schering AG Germany, which markets the product in the United States.

Princeton, New Jersey

Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The Company's lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial for the potential treatment of androgen independent prostate cancer. In addition to its therapeutic vaccines in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. Note: Acquisition of Corvas International approved by Dendreon shareholders on 7/29/2003.

Seattle, Washington

diaDexus, Inc., a privately held biotechnology company, is focused on the discovery, development and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify numerous disease-associated molecular targets.

South San Francisco, California

DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR's lead therapeutic product, orBec® (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed to treat inflammation in the mucosal lining of the intestine and stomach that can occur following allogeneic bone marrow and stem cell transplants.

1691 Michigan Ave Suite 435
Miami, Florida 33139

DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. The Company has five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. In addition to bicifadine for pain, those candidates address insomnia (indiplon, under license to Neurocrine and in Phase III development), anxiety (ocinaplon, joint ventured with Elan), angina and hypertension (joint development with Biovail) and depression (DOV 216-303, being developed in-house).

Hackensack, New Jersey

Dynavax Technologies is a biopharmaceutical company developing innovative products for treating and preventing allergy, inflammation-mediated diseases, infectious diseases and cancer. The company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Because ISS target the cause of many diseases - a faulty immune response - they represent a potential breakthrough in the treatment of immune-related disorders. ISS therapy is expected to be more effective, longer lasting, safer and more convenient than current treatments. With four ISS-based product candidates currently in clinical trials, Dynavax has established a leadership position in the research and development of novel therapies for a range of major immune-related disorders.

717 Potter Street, Suite 100
Berkeley, California 94710

ECR PHARMACEUTICALS markets both prescription and consumer products (which may be purchased without a prescription). Current therapeutic categories include oral analgesics, topical arthritis pain relievers, cough and cold medications, as well as products for seasonal allergies and contact dermatitis. Products are marketed nationwide, with most of ECR’s sales staff currently located in the southeastern and southwestern United States.

Richmond, Virginia

Eisai selects products for worldwide development that bring value to patients and their families and meet treatment needs. Worldwide, Eisai Co., Ltd. and its affiliates spend more than 15% of its revenue on research and development. Areas of study include immunology, endocrinology, gastroenterology, neurology, cardiology, pulmonology and oncology.

Teaneck, New Jersey

Elan Corporation, plc (Elan) began in 1969 with a vision: to approach the challenge of drug delivery from an entirely new angle—that of controlled absorption of a drug by the patient’s body. Over the years, Elan transitioned to become a world leader in drug delivery and specialty pharmaceuticals. Today, Elan has become a fully integrated biopharmaceutical company, pioneering exciting new research and development in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cancer, pain management and autoimmune diseases. It is focused on the discovery, development, and marketing of products and services in neurology, pain management, oncology, infectious disease and dermatology and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies.

Dublin, Ireland

Encysive Pharmaceuticals is a pharmaceutical company that discovers, develops and commercializes small molecule drugs aimed at cardiovascular and inflammatory diseases. Our research strategy focuses on the vascular endothelium, because of its importance in the evolution of a number of serious diseases for which current therapies are inadequate. Today, we are capitalizing on the approval of our first product, Argatroban, the R&D assets embedded in a full pipeline of promising drug candidates, and our growing clinical and business expertise to make the transition to a successful commercial operation.

6700 West Loop, 4th Floor
Bellaire, Texas 77401

A wholly owned subsidiary of Endo Pharmaceuticals Holdings (Nasdaq: ENDP, ENDPW), Endo Pharmaceuticals is a fully integrated specialty pharmaceutical company with market leadership in pain management products. The company researches, develops, produces and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike.

Chadds Ford, Pennsylvania

A leading biotechnology company engaged in the research, development, manufacturing and marketing of innovative health care products. Its three business subsidiaries are focused on early diagnosis, prevention and therapeutic treatment of disease. The company has concentrated on the development of enabling technologies in the areas of gene modification and gene regulation. In focusing its efforts in these areas, and in achieving patent protection for its technologies, Enzo has established the basis for a broad category of novel products, both diagnostic and therapeutic.

New York, New York

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat life-threatening diseases. The company has developed or acquired a number of marketed products, including ABELCET, which is marketed in North America by Enzon, and PEG-INTRON, marketed by Schering-Plough. Enzon’s product-focused strategy includes an extensive drug development program that leverages the Company’s PEG modification and single-chain antibody (SCA®) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products, projects, and technologies. Enzon has several drug candidates in various stages of development, independently and with partners.

Bridgewater, New Jersey

Eon Labs, Inc. is a generic pharmaceutical company engaged in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. An industry leader in obtaining Abbreviated New Drug Application, or ANDA, approvals from the U.S. Food and Drug Administration for new generic pharmaceutical products, Eon Labs' product line consists of nearly 250 products from more than 100 medications. Eon Labs' experienced management team utilizes an integrated approach to select and develop generic pharmaceutical products in both niche and high volume markets in order to be the first generic alternative to market and to obtain favorable market share. Eon Labs focuses on drugs in a broad range of solid oral dosage forms, utilizing both immediate and sustained release delivery.

Laurelton, New York

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, “HDL-C”, also known as the “good” cholesterol. The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company’s product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

3621 South State Street
Ann Arbor, Michigan 48108
  (734) 332-0506

EXACT Sciences Corporation is an applied genomics company located in Maynard, MA. Founded in 1995, the company's mission is to play a leading role in the eradication of common cancers by applying advances in the field of genomics to facilitate early detection of disease. EXACT Sciences believes its proprietary, genomics-based technologies will revolutionize the early detection of colorectal and other common cancers. EXACT Sciences believes that widespread and periodic application of these non-invasive technologies will reduce the mortality, morbidity and healthcare costs associated with these diseases.

100 Campus Drive
Marlborough, Massachusetts 01752

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.